News Focus
News Focus
icon url

oldmystic

12/21/22 1:52 PM

#393875 RE: georgejjl #393862

MayoMobile's EU angle makes a lot of sense.

F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth largest pharmaceutical company in the world by revenue,[5] and the leading provider of cancer treatments globally.[6][7]

The company controls the American biotechnology company Genentech, which is a wholly owned affiliate, and the Japanese biotechnology company Chugai Pharmaceuticals, as well as the United States-based companies Ventana and Foundation Medicine. Roche's revenues during fiscal year 2020 were 58.32 billion Swiss francs. Descendants of the founding Hoffmann and Oeri families own slightly over half of the bearer shares with voting rights (a pool of family shareholders 45%, and Maja Oeri a further 5% apart), with Swiss pharma firm Novartis owning a further third of its shares until 2021. Roche is one of the few companies increasing their dividend every year, for 2020 as the 34th consecutive year.

F. Hoffmann-La Roche is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).[8]
icon url

frrol

12/21/22 2:44 PM

#393886 RE: georgejjl #393862

No. It's a 24 minute podcast on impressions of trial results presented at CTAD. Anavex was discussed (by Grimmer only) for 2 minutes and in the context of possible combo therapy, the other 22 minutes was on the amyloid MABs.